Stoke Therapeutics
Update in progressSTOK (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Stoke Therapeutics develops treatments for severe genetic diseases by increasing protein production using its Targeted Augmentation of Nuclear Gene Output (TANGO) antisense oligonucleotides. Lead assets include STK-002 in Phase 1 for autosomal dominant optic atrophy and Zorevunersen (STK-001) in Phase 3 for Dravet syndrome. Partnerships with Biogen and Acadia. Formerly ASOthera, renamed in 2016. Founded 2014, based in Bedford, Massachusetts.
Company score
- Sentiment
- 0.50
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.43
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!